Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Circio Holding ASA AGM Information 2026

May 8, 2026

3769_rns_2026-05-08_351121d7-0c35-488c-9b30-64307b9b4eb7.html

AGM Information

Open in viewer

Opens in your device viewer

Circio Holding ASA: Minutes from the annual general meeting 2026

Circio Holding ASA: Minutes from the annual general meeting 2026

Oslo, 8 May 2026: Circio Holding ASA (the "Company") held its annual general

meeting today. The meeting was held as a physical meeting at the premises of

Advokatfirmaet Thommessen AS, Ruseløkkveien 38, 0251 Oslo, Norway.

All resolutions were made in accordance with the proposals from the board of

directors and the nomination committee, including, but not limited to,

approval of the 2025 annual accounts, election of KPMG as the Company's new

auditor and election of members to the board of directors.

The minutes from the annual general meeting are attached hereto and will also

be made available on the Company's website

circio.com/investors/general-meetings

(https://www.circio.com/en/section/investors/general-meetings/).

This information is subject to disclosure requirements pursuant to Section

5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: [email protected]

Lubor Gaal, CFO

Phone: +34 683 34 3811

Email: [email protected]

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 50-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.